Published in Clin J Am Soc Nephrol on August 12, 2010
Rituximab in the Treatment of Idiopathic Membranous Nephropathy | NCT00405340
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet (2013) 7.03
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011) 2.72
Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial. J Am Soc Nephrol (2015) 1.75
Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. J Am Soc Nephrol (2015) 1.48
Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 1.21
Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol (2013) 1.18
Glomerular diseases: membranous nephropathy--a modern view. Clin J Am Soc Nephrol (2013) 1.17
Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol (2013) 1.07
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol (2016) 1.02
IgG4-Related Disease Is Not Associated with Antibody to the Phospholipase A2 Receptor. Int J Rheumatol (2012) 0.99
Biologics for the treatment of autoimmune renal diseases. Nat Rev Nephrol (2016) 0.97
B Cell Reconstitution after Rituximab Treatment in Idiopathic Nephrotic Syndrome. J Am Soc Nephrol (2015) 0.91
Membranous nephropathy: the start of a paradigm shift. Curr Opin Nephrol Hypertens (2012) 0.91
Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient. Pediatr Nephrol (2013) 0.86
Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial Transplant (2012) 0.86
Triggers, bullets and targets, puzzle of membranous nephropathy. Nephrourol Mon (2012) 0.86
A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. J Am Soc Nephrol (2016) 0.81
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol (2014) 0.80
Treatment of membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol (2017) 0.80
A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol (2016) 0.79
Rituximab therapy for primary glomerulonephritis: Report on two cases. World J Clin Cases (2015) 0.79
Rituximab treatment for membranous nephropathy: a French clinical and serological retrospective study of 28 patients. Nephron Extra (2011) 0.79
Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol (2013) 0.78
Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Ther Adv Musculoskelet Dis (2014) 0.78
Pathogenic role of effector cells and immunoglobulins in cationic bovine serum albumin-induced membranous nephropathy. J Clin Immunol (2011) 0.78
Chapter 7: Idiopathic membranous nephropathy. Kidney Int Suppl (2011) (2012) 0.78
Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab. KI Rep (2016) 0.77
Alternative Pathway Dysregulation and the Conundrum of Complement Activation by IgG4 Immune Complexes in Membranous Nephropathy. Front Immunol (2016) 0.77
A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine. Clin J Am Soc Nephrol (2016) 0.75
B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J (2016) 0.75
Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2014) 0.75
Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease. Nephrology (Carlton) (2016) 0.75
Two cases of idiopathic membranous nephropathy treated with rituximab. Kidney Res Clin Pract (2013) 0.75
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. BMC Nephrol (2017) 0.75
Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal. Nephron (2016) 0.75
Management of Membranous Nephropathy in Asia. Kidney Dis (Basel) (2015) 0.75
Management of Membranous Nephropathy in Western Countries. Kidney Dis (Basel) (2015) 0.75
Infusion of autologous bone marrow mononuclear cells leads to transient reduction in proteinuria in treatment refractory patients with Idiopathic membranous nephropathy. BMC Nephrol (2013) 0.75
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int (2007) 3.52
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum (2005) 3.25
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.11
Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol (2010) 3.01
Rituximab treatment of idiopathic membranous nephropathy. Kidney Int (2007) 2.85
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2003) 2.32
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum (2004) 2.23
A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol (1998) 2.21
Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int (2001) 2.17
Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol (2005) 2.06
Rituximab for idiopathic membranous nephropathy. Lancet (2002) 2.03
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol (1999) 1.91
Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol (2003) 1.81
A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int (1995) 1.74
Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum (2008) 1.64
Differential B- and T-cell activation in Wegener's granulomatosis. J Allergy Clin Immunol (1999) 1.62
Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int (2005) 1.61
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol (2005) 1.58
Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2007) 1.49
Suppression of human B lymphocyte function by cyclophosphamide. J Immunol (1982) 1.46
Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant (2005) 1.42
Drug insight: rituximab in renal disease and transplantation. Nat Clin Pract Nephrol (2006) 1.41
Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis) J Am Soc Nephrol (1996) 1.38
Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest (1987) 1.31
B cells in autoimmunity. Arthritis Res Ther (2009) 1.13
Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis (2007) 1.03
Therapy: rituximab and PML risk-informed decisions needed! Nat Rev Rheumatol (2009) 0.84
Determinants of GFR depression in early membranous nephropathy. Am J Physiol Renal Physiol (2003) 0.83
[Regulatory T cells and systemic autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, primary Sjögren's syndrome]. Rev Med Interne (2009) 0.82
Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy. Am J Nephrol (1988) 0.80
Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med (2004) 11.52
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01
The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet (2002) 4.54
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol (2008) 4.10
Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA (2010) 4.05
Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol (2007) 3.66
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
Pneumocystis pneumonia in patients treated with rituximab. Chest (2013) 3.48
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 3.35
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med (2005) 3.18
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis (2004) 3.11
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int (2012) 2.85
Common variable immunodeficiency: a new look at an old disease. Lancet (2008) 2.75
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011) 2.72
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg (2002) 2.68
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem (2005) 2.64
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol (2010) 2.60
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int (2010) 2.51
Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med (2011) 2.42
Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc (2006) 2.37
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol (2008) 2.26
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum (2008) 2.26
Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. Urology (2011) 2.26
Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol (2005) 2.25
Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.22
Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. Chest (2013) 2.21
Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol (2011) 2.18
Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. Arthritis Rheum (2013) 2.17
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum (2012) 2.17
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis (2008) 2.12
Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation (2013) 2.10
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One (2008) 2.09
Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol (2010) 2.09
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med (2010) 2.06
Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum (2005) 2.03
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest (2013) 1.99
Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum (2012) 1.99
ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med (2007) 1.94
Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation (2008) 1.92
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol (2006) 1.91
Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood (2004) 1.91
Prevalence of renal artery and kidney abnormalities by computed tomography among healthy adults. Clin J Am Soc Nephrol (2010) 1.91
Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant (2007) 1.89
Clinical characteristics of potential kidney donors with asymptomatic kidney stones. Nephrol Dial Transplant (2011) 1.87
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney Int (2013) 1.84
Pulmonary involvement in Henoch-Schönlein purpura. Mayo Clin Proc (2004) 1.83
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma (2010) 1.78
Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis. Am J Kidney Dis (2008) 1.77
Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol (2006) 1.75
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest (2013) 1.74
Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med (2007) 1.73
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol (2008) 1.73
Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol (2008) 1.73
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64
Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int (2008) 1.64
Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum (2006) 1.64
Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery (2011) 1.64
Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney Int (2013) 1.63
Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int (2011) 1.63
Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol (2002) 1.62
Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int (2004) 1.62